Ergoteles’s Adaptive Biotechnologies ADPT Stock Holding History

Ergoteles’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-47,500	Closed	-$659K	–	1602
2022 Q1	$659K	Buy	47,500 +5,837	+14%	+$91.8K	0.02%	573
2021 Q4	$1.17M	Buy	+41,663	New	+$1.28M	0.05%	375
2021 Q2	–	Sell	-179,680	Closed	-$7.23M	–	1459
2021 Q1	$7.23M	Buy	+179,680	New	+$9.73M	0.23%	119

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

Ergoteles's ADPT Position: Q2 2022 in Review

Ergoteles sold out of Adaptive Biotechnologies (ADPT) in Q2 2022, closing a stake of 47,500 shares — an estimated $659K sold.

Ergoteles first reported a position in ADPT in Q1 2021 and held it in 3 quarters. The position peaked at $7.23M in Q1 2021. 209 funds tracked by Wall St. Rank hold ADPT as of Q2 2022.

Ergoteles reported no remaining Adaptive Biotechnologies position as of Q2 2022 after selling out during the quarter.
Ergoteles sold 47,500 Adaptive Biotechnologies shares in Q2 2022, an estimated $659K.
Ergoteles first reported a position in Adaptive Biotechnologies in Q1 2021 and held it in 3 quarters.
Ergoteles's Adaptive Biotechnologies position peaked at $7.23M in Q1 2021.
209 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2022.

Based on Ergoteles's 13F filing for Q2 2022, filed 12 Aug 2022.